CN115404202A - Method for obtaining spinal cord motor neurons by using human pluripotent stem cell induction and application of method in mitochondria visualization - Google Patents
Method for obtaining spinal cord motor neurons by using human pluripotent stem cell induction and application of method in mitochondria visualization Download PDFInfo
- Publication number
- CN115404202A CN115404202A CN202210943465.5A CN202210943465A CN115404202A CN 115404202 A CN115404202 A CN 115404202A CN 202210943465 A CN202210943465 A CN 202210943465A CN 115404202 A CN115404202 A CN 115404202A
- Authority
- CN
- China
- Prior art keywords
- motor neurons
- volume fraction
- pluripotent stem
- spinal
- spinal cord
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002161 motor neuron Anatomy 0.000 title claims abstract description 114
- 238000000034 method Methods 0.000 title claims abstract description 39
- 210000000278 spinal cord Anatomy 0.000 title claims abstract description 39
- 210000003470 mitochondria Anatomy 0.000 title claims abstract description 36
- 210000001778 pluripotent stem cell Anatomy 0.000 title claims abstract description 27
- 230000006698 induction Effects 0.000 title claims abstract description 11
- 238000012800 visualization Methods 0.000 title abstract description 5
- 230000004069 differentiation Effects 0.000 claims abstract description 36
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 9
- 230000007246 mechanism Effects 0.000 claims abstract description 5
- 238000007877 drug screening Methods 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 41
- 239000002609 medium Substances 0.000 claims description 33
- 239000001963 growth medium Substances 0.000 claims description 31
- 239000003112 inhibitor Substances 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 27
- 150000003384 small molecules Chemical class 0.000 claims description 23
- 230000001939 inductive effect Effects 0.000 claims description 22
- 210000000461 neuroepithelial cell Anatomy 0.000 claims description 21
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 16
- 239000000556 agonist Substances 0.000 claims description 13
- 238000012423 maintenance Methods 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 12
- 102000001267 GSK3 Human genes 0.000 claims description 10
- 108060006662 GSK3 Proteins 0.000 claims description 10
- 239000012190 activator Substances 0.000 claims description 10
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 claims description 10
- 230000000508 neurotrophic effect Effects 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 7
- 229910001424 calcium ion Inorganic materials 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 108010085895 Laminin Proteins 0.000 claims description 6
- 230000035800 maturation Effects 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 4
- FHYUGAJXYORMHI-UHFFFAOYSA-N SB 431542 Chemical compound C1=CC(C(=O)N)=CC=C1C1=NC(C=2C=C3OCOC3=CC=2)=C(C=2N=CC=CC=2)N1 FHYUGAJXYORMHI-UHFFFAOYSA-N 0.000 claims description 4
- 108010076089 accutase Proteins 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 108010082117 matrigel Proteins 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- JMIFGARJSWXZSH-UHFFFAOYSA-N DMH1 Chemical compound C1=CC(OC(C)C)=CC=C1C1=CN2N=CC(C=3C4=CC=CC=C4N=CC=3)=C2N=C1 JMIFGARJSWXZSH-UHFFFAOYSA-N 0.000 claims description 3
- 108010047294 Lamins Proteins 0.000 claims description 3
- 208000001738 Nervous System Trauma Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 238000004115 adherent culture Methods 0.000 claims description 3
- 229940121657 clinical drug Drugs 0.000 claims description 3
- 210000005053 lamin Anatomy 0.000 claims description 3
- 230000004898 mitochondrial function Effects 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 238000004114 suspension culture Methods 0.000 claims description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 2
- 208000020764 Sensation disease Diseases 0.000 claims description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 230000000857 drug effect Effects 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 102000006835 Lamins Human genes 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 abstract description 32
- 208000005264 motor neuron disease Diseases 0.000 abstract description 10
- 208000015122 neurodegenerative disease Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 238000010186 staining Methods 0.000 abstract description 3
- 238000010859 live-cell imaging Methods 0.000 abstract description 2
- 238000011269 treatment regimen Methods 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 19
- 102220542676 Putative uncharacterized protein FLJ46641_D90A_mutation Human genes 0.000 description 18
- 238000003125 immunofluorescent labeling Methods 0.000 description 16
- 230000033001 locomotion Effects 0.000 description 13
- 239000008055 phosphate buffer solution Substances 0.000 description 13
- 239000007850 fluorescent dye Substances 0.000 description 12
- 210000002569 neuron Anatomy 0.000 description 11
- 239000000975 dye Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- 241000283074 Equus asinus Species 0.000 description 8
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 8
- PFYWPQMAWCYNGW-UHFFFAOYSA-M [6-(dimethylamino)-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]-dimethylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.COC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 PFYWPQMAWCYNGW-UHFFFAOYSA-M 0.000 description 8
- 210000003050 axon Anatomy 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 102100021796 Sonic hedgehog protein Human genes 0.000 description 7
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 7
- 239000007640 basal medium Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- APERIXFHHNDFQV-UHFFFAOYSA-N [2-[2-[2-[bis(carboxymethyl)amino]-5-methylphenoxy]ethoxy]-4-[3,6-bis(dimethylamino)xanthen-9-ylidene]cyclohexa-2,5-dien-1-ylidene]-bis(carboxymethyl)azanium;chloride Chemical compound [Cl-].C12=CC=C(N(C)C)C=C2OC2=CC(N(C)C)=CC=C2C1=C(C=1)C=CC(=[N+](CC(O)=O)CC(O)=O)C=1OCCOC1=CC(C)=CC=C1N(CC(O)=O)CC(O)=O APERIXFHHNDFQV-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000008410 smoothened signaling pathway Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- RUVJFMSQTCEAAB-UHFFFAOYSA-M 2-[3-[5,6-dichloro-1,3-bis[[4-(chloromethyl)phenyl]methyl]benzimidazol-2-ylidene]prop-1-enyl]-3-methyl-1,3-benzoxazol-3-ium;chloride Chemical compound [Cl-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C(N(C1=CC(Cl)=C(Cl)C=C11)CC=2C=CC(CCl)=CC=2)N1CC1=CC=C(CCl)C=C1 RUVJFMSQTCEAAB-UHFFFAOYSA-M 0.000 description 4
- 208000026072 Motor neurone disease Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004065 mitochondrial dysfunction Effects 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012103 Alexa Fluor 488 Substances 0.000 description 3
- 101100234822 Caenorhabditis elegans ltd-1 gene Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 description 3
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 3
- 102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 3
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 3
- 230000004094 calcium homeostasis Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000012110 Alexa Fluor 594 Substances 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 2
- 108020005198 Long Noncoding RNA Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100026531 Prelamin-A/C Human genes 0.000 description 2
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000008335 axon cargo transport Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000026326 mitochondrial transport Effects 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000002241 progressive bulbar palsy Diseases 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000007441 retrograde transport Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 101150062190 sod1 gene Proteins 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 108700030955 C9orf72 Proteins 0.000 description 1
- 101150014718 C9orf72 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102100029301 Guanine nucleotide exchange factor C9orf72 Human genes 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- AVIMZJSOKOECPQ-UHFFFAOYSA-N N-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]-4-(2-morpholin-4-ylethoxy)benzamide Chemical compound C1=C2N(CC)C(C=3C(=NON=3)N)=NC2=CN=C1NC(=O)C(C=C1)=CC=C1OCCN1CCOCC1 AVIMZJSOKOECPQ-UHFFFAOYSA-N 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 102000003890 RNA-binding protein FUS Human genes 0.000 description 1
- 108090000292 RNA-binding protein FUS Proteins 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 1
- 101150014554 TARDBP gene Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 201000008257 amyotrophic lateral sclerosis type 1 Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002226 anterior horn cell Anatomy 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000024683 calcium ion homeostasis Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002194 freeze distillation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 101150090422 gsk-3 gene Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 210000001153 interneuron Anatomy 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- FYBHCRQFSFYWPY-UHFFFAOYSA-N purmorphamine Chemical compound C1CCCCC1N1C2=NC(OC=3C4=CC=CC=C4C=CC=3)=NC(NC=3C=CC(=CC=3)N3CCOCC3)=C2N=C1 FYBHCRQFSFYWPY-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000019929 sporadic amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a method for obtaining spinal cord motor neurons by using human pluripotent stem cell induction and mitochondrion visualization application thereof, and relates to the technical field of differentiation induction of pluripotent stem cells. Mitochondrial responses to different drug treatments were detected by mitochondrial staining of mature spinal motor neurons, live cell imaging, and. Can be used for researching related action mechanism of mitochondria in motor neuron diseases and establishing a drug screening platform; is beneficial to producing various medicines for treating neurodegenerative diseases and provides new diagnostic tools and treatment strategies for the neurodegenerative diseases.
Description
Technical Field
The invention relates to the technical field of differentiation induction of pluripotent stem cells, in particular to a method for obtaining spinal motor neurons by using human pluripotent stem cells and application thereof.
Background
Motor Neurons (MN) are a special type of neurons in the central nervous system, mainly located in the cerebral cortex, brainstem and spinal cord, and are the basic units that control the movement of the body. Motor Neuron Disease (MND), a group of chronic degenerative diseases whose etiology has not been clear selectively invading the anterior horn cells of the spinal cord, the motor neurons of the brain stem, the cortical vertebral body cells and the vertebral bundles; its pathology is characterized by the degeneration, necrosis and apoptosis of the progressive upper and lower motor neurons. Different types of motor neuron diseases are formed due to different combinations of symptoms and signs, and comprise Amyotrophic Lateral Sclerosis (ALS), spinal Muscular Atrophy (SMA), primary Lateral Sclerosis (PLS), progressive Bulbar Palsy (PBP) and the like, wherein the ALS is the most common type of chronic motor neuron diseases, is commonly called as 'progressive freezing human disease', is one of five major absolute diseases recognized globally, is a fatal delayed neurodegenerative disease, selectively attacks upper and lower motor neurons of brain and spinal cord, and is clinically manifested by gradually-aggravated muscular atrophy and muscle weakness, even can cause difficulty in speaking, swallowing and breathing, and finally endangers life, and at present, no method for curing the ALS exists. ALS is divided into familial amyotrophic lateral sclerosis (familial ALS, faals) and sporadic amyotrophic lateral sclerosis (sporadic ALS, sALS). To date, more than 30 genes have been associated with fALS, including the common genes SOD1, C9orf72, FUS and TDP43 mutations accounting for 50% -70% of fALS, with SOD1 gene mutations accounting for 20% of fALS. The SOD1 gene is the ALS related gene which is discovered for the first time in 1993, and SOD1 protein is mainly positioned in the membrane gap of cytoplasm and mitochondria and is involved in regulating and controlling the dynamic processes of mitochondrial fusion and cleavage, movement, energy metabolism and the like, which means that the damage of mitochondrial dynamics can cause the degeneration of mitochondria due to the morphological and functional disorder of the mitochondria and the subsequent generation of neurons.
It is reported in literature that the mutant SOD1 protein is unstable in conformation and is easy to be misfolded, so that the mutant SOD1 protein is aggregated, and ALS motor neurons are degraded. In addition, misfolded SOD1 protein can impair mitochondrial function, leading to altered mitochondrial morphology and swelling, vacuoles and swelling in the mitochondrial matrix. Thread pelletThe body plays a key role in the survival and metabolism of cells, and is the site of oxidative phosphorylation of cells to produce Adenosine Triphosphate (ATP) which provides energy. Neurons are highly polarized cells with high metabolic demand, with the brain accounting for only 2% of the body mass, but consuming 20% of the body's ATP at rest. Neurons meet their high metabolic needs primarily by synthesizing ATP through oxidative phosphorylation, which makes neurons more prone to mitochondrial dysfunction. Such abnormalities can lead to dysfunction of motor neuron cells, eventually leading to apoptosis. The ALS rats and ALS patients have reports on the change of ultrastructural morphology of mitochondria such as motor neurons, muscles, brain tissues, lymphocytes, livers and the like and dysfunction of an electron transfer system. The mutated SOD1 results in a decrease in respiratory chain complex I, IV activity and a decrease in ATP production. Thus, abnormalities in ATP and ROS production, energy and calcium homeostasis, induction of apoptosis, and mitochondrial transport in axons were found in ALS transgenic mice and patients. ALS patients with SOD1 mutations have Ca deficiency in motor neurons 2+ Binding protein expression, resulting in cellular pair Ca 2+ Decreased uptake and increased neuronal excitability. Neurons, especially the synaptic terminal regions, need to rely on massive synthesis of ATP within the mitochondria and calcium homeostasis to maintain their function. Therefore, in these areas of high ATP demand and calcium homeostasis, mitochondrial transport is of paramount importance, and defects in mitochondrial axonal transport lead to abnormal neuronal metabolism.
An increasing number of literature studies have demonstrated that mitochondrial dysfunction drives or mediates the pathological processes of neurodegenerative diseases including ALS. In rats with SOD 1G 93A mutation, mutant SOD1 causes oxidative stress, protein aggregation, and neuronal excitotoxicity, eventually leading to motor neuron degeneration. Human pluripotent stem cells (hpscs) are pluripotent cells with self-renewal and self-replication capabilities, which can be differentiated into other somatic cells and mimic the pathogenesis of diseases, so the hPSC differentiation technology provides a good platform for studying ALS pathogenesis. In particular, hpscs can study mitochondrial dysfunction in the early pathological processes of ALS by providing valuable models of human motor neurons through directed differentiation.
In the prior art, the literature "Temporal expression profiles of lncRNA and mRNA in human embryonic stem cell-derived motor neurons degradation differentiation" (Xuejiao Sun, ming-Xing Li, etc., 2020 Nov.13) discloses Temporal expression profiles of lncRNA and mRNA during differentiation of human embryonic stem cell-derived motor neurons, and motor neurons with a purity of more than 90% are harvested from hESCs. However, the SHH agonist (Purmorphamine) used in this document is highly toxic, and therefore, we chose to use another SHH Agonist (SAG).
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a method for obtaining spinal motor neurons by using human pluripotent stem cell induction, which comprises the steps of firstly utilizing an induced differentiation culture medium to induce and differentiate human pluripotent stem cells (hPSC) to obtain neuroepithelial cells (NEP), then utilizing a patterned culture medium to induce and differentiate NEP to obtain spinal motor neuron progenitor cells, and then utilizing a maintenance patterned culture medium to induce and differentiate the spinal motor neuron progenitor cells to obtain HB9 + Spinal motor neurons, eventually undergoing neurotrophic maturation to obtain CHAT + Spinal motor neurons. The spinal cord motor neuron obtained by the method provided by the invention can be used for comprehensively and deeply researching the cell dysfunction of the motor neuron disease, researching the action mechanism related to mitochondria in the motor neuron disease by the mitochondria visualization application of the motor neuron, and establishing a drug screening platform. The method is helpful for screening clinical drugs, producing and preparing various drugs for treating neurodegenerative diseases, providing a new diagnosis tool and a new treatment strategy for the neurodegenerative diseases, and preventing and treating various neurodegenerative diseases, and is realized by the following technology.
A method for inducing and obtaining spinal cord motor neurons by using human pluripotent stem cells comprises the following steps:
s1, adding human pluripotent stem cells into an induced differentiation culture medium containing a first small molecule composition, and inducing and differentiating to obtain neuroepithelial cells;
the first small molecule composition comprises a GSK3 inhibitor, a TGF-beta/Smad inhibitor and a BMP inhibitor;
s2, adding the neuroepithelial cells obtained in the step S1 into a patterned culture medium containing a second small molecule composition, and inducing and differentiating to obtain spinal cord motor neuron progenitor cells;
the second small molecule composition comprises a GSK3 inhibitor, a TGF- β/Smad inhibitor, a BMP inhibitor, a RAR nuclear receptor activator, and a SHH agonist (Sonic hedgehog/Smoothened signaling pathway agonist);
in the actual operation of the step S2, all the products of the step S1 may be directly added to the maintenance patterned culture medium for direct culture, or the neuroepithelial cells NEP may be separated and purified by a certain technique, and then added to the maintenance patterned culture medium for induced differentiation to obtain the spinal motoneuron cells;
s3, adding the spinal cord motor neuron progenitor cells obtained in the step S2 into a maintenance patterned culture medium containing a third small molecule composition for suspension culture, and inducing differentiation to obtain HB9 + Spinal motor neurons;
the third small molecule composition comprises a RAR nuclear receptor activator and a SHH agonist;
step S3, in actual operation, all products obtained in step S2 can be directly added into a maintenance patterned culture medium, or spinal cord motor neuron progenitor cells can be separated and purified by a certain technology and then added into the maintenance patterned culture medium;
s4, taking the HB9 obtained in the step S3 + Culturing spinal cord motor neuron by adherence, performing neurotrophic maturation to obtain CHAT + Spinal motor neurons.
In the actual operation of step S4, all the products obtained in step S3 may be added directly to the neurotrophic medium, or HB9 may be isolated and purified first by a technique + Spinal cord motor neurons, which are then added to the neurotrophic medium.
Preferably, in step S1, the differentiation-inducing medium comprises DMEM/F12 and Neurobasal in a volume ratio of 1:1, and further comprises GlutaMax with a volume fraction of 1%, B27 with a volume fraction of 1%, N-2 with a volume fraction of 0.5%, AA with a volume fraction of 0.1mM, GSK3 inhibitor with a volume fraction of 3 μ M, TGF- β/Smad inhibitor with a volume fraction of 2 μ M, BMP inhibitor with a volume fraction of 2 μ M.
Preferably, in step S2, the patterned medium comprises DMEM/F12 and Neurobasal in a volume ratio of 1.
More preferably, in step S2, the second small molecule composition comprises CHIR99021 (GSK 3 inhibitor), DMH-1 (BMP inhibitor), SB431542 (TGF-. Beta./Smad inhibitor), RA (RAR nuclear receptor activator), and SAG (SHH agonist).
Preferably, in step S3, the maintenance patterning medium comprises DMEM/F12 and Neurobasal in a volume ratio of 1.
Preferably, step S4 is specifically: after inducing differentiation for 5 days by the method of step S3, the sterile round slide was placed in a well plate, and PLO solution was dropped on the slide at 37 ℃ and 5% CO 2 Incubating overnight under the environment; absorbing and removing PLO the following day, washing, adding Laminin solution dropwise onto the slide, or using precooled Matrigel alone, and making the content of CO 5% at 37 ℃% 2 Continuously incubating for more than 1h under the environment; finally, digesting the large neurosphere into a single spinal cord motor neuron or a small neurosphere by using cell digestive juice Accutase; inoculating the suspension of spinal motor neurons or small neurospheres on a slide treated by PLO/Lamin or Matrigel for adherent culture for 6-10 days, carrying out neurotrophic maturation to obtain the expression CHAT + Spinal motor neurons.
More preferably, in step S4, the components of the medium used for neurotrophic, including Neurobasal, further include GlutaMax at a volume fraction of 1%, N-2 at a volume fraction of 0.5%, B27 at a volume fraction of 1%, AA at 0.1mM, SAG at 0.1. Mu.M, RA at 0.01. Mu.M, IGF-1 at 10ng/mL, CNTF at 0.1. Mu.M, compound E at 10ng/mL, BDNF at 10ng/mL and GDNF at 10 ng/mL.
In the above step S4, HB9 + Spinal motor neurons may or may not be subjected to Accutase digestion for 7-10min optimal to yield a suspension of neurospheres containing on average about 50 cells per neurosphere.
It is noted that the first small molecule combinations provided by the present invention are selected from GSK3 inhibitors, TGF- β/Smad inhibitors and BMP inhibitors, i.e. selected from substances capable of inhibiting the GSK3, TGF- β/Smad and BMP signaling pathways, respectively. For example, although CHIR99021, DMH-1, SB431542 and their derivatives are preferable in the present invention, the above three pathways can be inhibited to achieve the corresponding culture purpose, and the concentrations of the three are not particularly limited; for example, it may be 3. Mu.M, 2. Mu.M and 2. Mu.M, respectively, but is not limited thereto.
The second small molecule composition is selected from a GSK3 inhibitor, a TGF-beta/Smad inhibitor, a BMP inhibitor, an RAR nuclear receptor activator and an SHH agonist, for example, CHIR99021, SB431542, RA and SAG can be preferable in the present invention, and the concentration thereof is not particularly limited as long as the purpose of inhibiting GSK3, TGF-beta/Smad and BMP signaling pathways, activating RAR nuclear receptors and inhibiting SHH signaling pathways can be achieved; for example, 1. Mu.M GSK3 inhibitor, 2. Mu.M BMP inhibitor, 2. Mu.M TGF-. Beta./Smad inhibitor, 0.1. Mu.M RAR nuclear receptor activator, and 1. Mu.M SHH agonist can be selected, but not limited thereto.
The third small molecule composition may be selected from an activator of RAR nuclear receptor and an agonist of SHH signaling pathway, for example, the present invention may preferably be RA, SAG and their derivatives, and the concentration thereof is not particularly limited as long as it can activate RAR nuclear receptor and SHH signaling pathway, and for example, 0.01. Mu.M of RAR nuclear receptor activator and 0.1. Mu.M of SHH signaling pathway agonist may be optimally selected, but not limited thereto.
The invention also provides a spinal cord motor neuron obtained by any one of the methods.
A composition or kit for obtaining spinal cord motor neurons by inducing human pluripotent stem cells, the composition or kit comprising the first small molecule composition, the second small molecule composition and the third small molecule composition provided in the method.
The spinal cord motor neuron is prepared by any one of the methods and used for researching the function change of mitochondria by dynamically observing the density, the motion state, the membrane potential and the intuitive change of the calcium ion concentration of the mitochondria of the spinal cord motor neuron, thereby evaluating the action of a medicament and screening clinical medicaments; for example, mito-tracker/TMRM/Rhod-2-AM and other dyes can be used for staining living cell mitochondria of spinal motor neurons, the density of the mitochondria of the spinal motor neurons can be dynamically observed in real time under a confocal microscope by applying or withdrawing drugs, and the change of functions of the mitochondria can be reflected by the intuitive change of the motion along axons, membrane potential and calcium ion concentration, so that the drug effect can be evaluated, and clinical drugs can be screened; or for preparing a medicament for treating spinal cord motor neuron loss or imbalance and dyskinesia and/or sensory disturbance caused by nervous system diseases or injuries; or used for pathological mechanism research and drug screening of the diseases.
Compared with the prior art, the invention has the advantages that: the invention provides a method for obtaining spinal cord motor neurons by a series of induced differentiation by utilizing human pluripotent stem cells. Compared with the method disclosed at present, the method provided by the invention has the advantages that the purity and yield of the finally obtained spinal cord motor neurons are higher by changing the raw material components of the culture medium at each stage. The spinal cord motor neuron and the mitochondrial visualization of the motor neuron can be widely applied to the research of pathological mechanisms of motor disorder and/or sensory disorder diseases caused by motor neuron diseases, neurodegenerative diseases and nervous system diseases or injuries and the research and the development of related medicaments.
Drawings
FIG. 1 is a flow chart of differentiation of hPSCs into spinal motor neurons;
FIG. 2 is a photograph showing immunofluorescence staining of cells obtained by inducing differentiation at each stage; wherein, FIG. 2-A is an immunofluorescence staining chart of NEP cell positive marker SOX1 (red) and nucleus marker Hochest (blue); FIG. 2-B is an immunofluorescence staining pattern of MNP cell positive marker Olig2 (green), nuclear marker Hochest (blue); FIG. 2-C is an immunofluorescence staining pattern for the spinal cord motor neuron positive marker HB9 (green), the neurofilament heavy chain marker NF200 (red); FIG. 2-D is a graph showing immunofluorescent staining of the positive marker CHAT (green) and the nuclear marker (Hochest) of mature motor neurons;
FIG. 3 is a graph of the distribution and size of mitochondria of D90D and D90A motor neurons on axons;
FIG. 4 is a graph of mitochondrial movement of D90D and D90A motor neurons;
FIG. 5 shows mitochondrial membrane potential changes in SOD1D 90A motoneurons;
FIG. 6 shows Ca placement into D90D and D90A motor neurons 2+ The change of concentration;
FIG. 7 is qRT-PCR of BCL-2, BCL-XL, BCL and BAX in spinal cord motor neurons; * P < 0.01.
Detailed Description
The technical solutions of the present invention will be described clearly and completely below, and it should be apparent that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The method for obtaining the glutamatergic interneurons of the spinal cord by inducing using the human pluripotent stem cells provided in the following embodiments mainly comprises four steps: (1) Utilizing primary hPSCs (human pluripotent stem cells) to induce and differentiate to obtain neuroepithelial NEP; (2) Inducing differentiation to obtain spinal motor neuron progenitor cells; (3) Inducing differentiation to obtain HB9 + Spinal motor neurons; (4) Culturing and maturing under adherent conditions to obtain CHAT + Spinal motor neurons.
1. Materials, instruments and apparatus
(1) Mice pregnant for 11.5 days: CF1 strain, purchased from shanghai slek laboratory animals llc.
(2) Human embryonic stem cell lines: h9 line (cell passage number 23-50).
(3) Inducible pluripotent stem cell lines: SOD1D 90A (cell passage number 20-50), SOD1D90D (cell passage number 20-50), cell line all derive from Zhang Su Chun professor laboratory friend situation of Wisconsin stem cell research center of USA and provide.
(3) Reagent and consumable
The reagent materials and consumables purchased are shown in table 1 below.
TABLE 1 procurement of reagent materials and consumables
The instruments, devices and apparatus used are shown in table 2 below.
TABLE 2 instruments, devices and instruments used
Name of instrument | Manufacturer(s) of |
Confocal microscope | Olympus Corp |
Fluorescence inversion/righting microscope | Olympus Corp |
Optical microscope | Thermo of Nikon corporation |
CO 2 Cell culture box | Thermo of Fisher corporation |
Biological safety cabinet | Fisher Co Ltd |
Electric liquid transfer device | Eppendorf Co Ltd |
Manual liquid transfer device | Eppendorf/Thermo Fisher Co |
1.5ml freezing tube | Corning Ltd |
0.22 mu m sterile filter | Millipore Corp |
Ultra-low temperature refrigerator at minus 80 DEG C | Panasonic corporation |
Culture dish (35/60/100 mm) | |
6 orifice plate/12 orifice plate/24 orifice plate | Corning Corp Ltd |
T25/T75 culture bottle | Eppendorf Co Ltd |
Pipet (5/10/25 ml) | Thermo Fisher Co Ltd |
Disposable syringe (5/25 ml) | Corning Ltd |
Water bath pot | Juzhou megasai laboratory devices manufacturing company |
The antibodies used are shown in table 3 below.
Antibodies used in Table 3
Name of antibody | Company and goods number | Species and dilution ratio |
Sheep anti-SOX1 antibody | R&Company D | 1:1000 |
Rabbit anti-HOXA3 | Sigma Co Ltd | 1:1000 |
Rabbit anti-OLIG2 | Millipore Corp | 1:500 |
Mouse anti-HB9 | Sigma Co Ltd | 1:500 |
Mouse anti-NF200 | CST Corp Ltd | 1:400 |
Sheep anti-CHAT | Millipore Corp | 1:500 |
Donkey anti-sheep Alexa Fluor 488 | Invitrogen corporation | 1:2000 |
Donkey anti-rabbit Alexa Fluor 488 | Invitrogen corporation | 1:2000 |
Donkey anti-mouse Alexa Fluor 488 | Invitrogen corporation | 1:2000 |
Donkey anti-rabbit Alexa Fluor 594 | Invitrogen corporation | 1:2000 |
Donkey anti-mouse Alexa Fluor 594 | Invitrogen corporation | 1:2000 |
Hoechst 33342 | Invitrogen corporation | 1:1000 |
Mito-Tracker Green | Thermo Fisher Co Ltd | |
TMRM | Thermo Fisher Co Ltd | |
Rhod-2-AM | Thermo Fisher Co Ltd | |
Fluo-4-AM | Thermo Fisher Co Ltd |
The self-prepared reagents, culture medium materials are shown in table 4 below.
TABLE 4 self-prepared reagents and media
2. Test method
FIG. 1 is a flow chart of the cell differentiation process provided by the present invention. Each stage is 6 days, and HB9 is obtained after 18 days + Spinal motor neurons.
FIG. 2 is a photograph showing immunofluorescent staining of cells obtained by induced differentiation at each stage; wherein FIG. 2-A is an immunofluorescence staining pattern of NEP cell positive marker SOX1 (red), nuclear marker Hochest (blue); FIG. 2-B is an immunofluorescence staining pattern of MNP cell positive marker Olig2 (green) and nuclear marker Hochest (blue); FIG. 2-C is an immunofluorescence staining pattern for the spinal cord motor neuron positive marker HB9 (green), the neurofilament heavy chain marker NF200 (red); FIG. 2-D is a graph showing immunofluorescent staining of positive markers CHAT (green) and nuclear markers (hochests) of mature motor neurons.
(1) Primary culture of Mouse Embryonic Fibroblasts (MEFs)
(1) A Mouse Embryo Fibroblast (MEF) basal medium prepared in advance according to the formulation of table 4 above;
(2) killing mice pregnant for 13.5 days by a neck breaking method, exposing and taking out a beaded uterus, placing the beaded uterus in a 10cm culture dish containing PBS, and washing off bloodstain, fat connective tissue and the like;
(3) cutting the uterine wall, taking out embryos one by one, stripping fetal membrane tissues, taking out fetal rats, and sequentially placing the fetal rats in a 6cm culture dish containing PBS (phosphate buffer solution);
(4) cutting off the head, limbs, tail and internal organs of a fetal rat, and then placing the trunk of the fetal rat in a 6cm culture dish containing PBS;
(5) cutting fetal mouse trunk to 1mm 3 Adding 0.25% trypsin, sterilizing in an incubator at 37 ℃ for about 20min, periodically blowing with a gun head during the digestion to make the tissue block as small as possible, adding a prepared MEF basal medium with the same volume to stop digestion, and centrifuging at 1000rpm for 5min;
(6) discarding the supernatant, and inoculating the digested cells into a culture dish of 10 cm; typically, one embryo is inoculated into one petri dish.
(2) MEF cell subculture
(1) When the density of MEF cells is observed to reach about 90%, passage can be carried out;
(2) discard old culture medium and rinse 2 times with PBS medium, then add 0.05% trypsin 2.5mL, at 37 deg.C, 5% CO 2 Digesting in the incubator for 3-5min;
(3) observing under a microscope, when the cells become round and float, immediately adding an equal volume of MEF basal medium to stop digestion, and blowing to form a single cell suspension;
(4) transferring MEF cells into a 15ml centrifuge tube, centrifuging at 1000rpm for 5min, and removing supernatant;
(5) add MEF basal medium to resuspend, inoculate to a new dish at a ratio of 1 2 And (5) culturing in a cell culture box.
(3) MEF cell irradiation
(1) When the third generation of cells overgrow to 90%, digesting MEF cells with 0.05% trypsin, adding an equal volume of MEF basal medium for neutralization, and then transferring into a 50mL centrifuge tube;
(2) irradiating MEF cells by gamma rays, wherein the total dose of the gamma rays reaches 40Gy;
(3) centrifuging the irradiated MEF cell suspension at 1000rpm for 6min;
(4) removing supernatant, resuspending cells with prepared cell freezing solution, placing into freezing box, and placing into-80 deg.C refrigerator overnight;
(5) the next day, the cryopreserved cells were placed in liquid nitrogen for long term cryopreservation.
(4) Cell culture and passage of human pluripotent stem cell hPSC
(1) Preparing a primary maintenance medium of human pluripotent stem cells (hPSCs) and a 0.1% gelatin solution in advance according to the formula of the above table 4;
(2) uniformly spreading 1mL per well of a six-well plate with 0.1% gelatin solution, placing at 37 deg.C, 5% CO 2 Incubating in an incubator for at least 30min;
(3) sucking off gelatin solution, adding MEF basal medium, recovering MEF cells irradiated with radiation at a rate of 2.5 × 10 per well 5 Inoculating each cell in a six-well plate, mixing, placing at 37 deg.C, 5% CO 2 Culturing in an incubator overnight;
(4) the next day, the MEF basal medium was aspirated off, the hpscs were subsequently seeded onto MEF cells, and 2ml per well of hPSC primary maintenance medium was added to culture the expanded hpscs;
(5) the culture medium is changed every day, the hPSCs are digested by dispase enzyme solution about 5-7 days, and then are subcultured on MEF cells according to the following passage ratio of 1.
(5) Differentiation of hPSCs into neuroepithelial cells (NEPs)
(1) Preparing an induced differentiation medium of NEP in advance according to the formula of the table 4;
(2) on the next day after the hPSC subculture, the hPSC medium was changed to an induced differentiation medium, and differentiation at the neuroepithelial cell stage was started, which was designated as NEP differentiation day 0;
(3) place the cells at 37 ℃ 5% CO 2 In the cell culture box, the liquid is changed every other day, and the NEP cells can be differentiated after 6 days of culture.
(6) NEP differentiation into spinal cord motor neuron progenitor cells (MNP)
(1) MEF cells were plated on six-well plates one day in advance; preparing a patterned culture medium in advance according to the formula in the table 4 above;
(2) on day 6 of NEP differentiation, NEP cells were digested with dispase enzyme solution, incubated at 37 ℃ and 5% CO 2 Digesting in the incubator for 3min, then bringing NEP cloning and crimping, washing out the enzyme solution, and then washing twice with DMEM/F-12 solution;
(3) using a patterned culture medium, inoculating the MEF cells according to the ratio of 1;
(4) place the cells at 37 ℃ 5% CO 2 And in the cell culture box, changing the liquid every other day, and culturing for 6 days to differentiate into the MNP.
(7) MNP to HB9 + Spinal motor neuron differentiation
(1) Preparing a maintenance modeling culture medium in advance according to the formula of the table 4;
(2) on day 6 of MNP differentiation, resuspending the MNP by using MN culture medium, inoculating the MNP into a T25 culture flask for suspension culture, and changing the culture medium every other day, wherein the MNP stage is counted as day 0;
(3) placing the cells in a CO2 cell culture box at 37 deg.C, 5%;
(4) day 5 of differentiation, sterile round slides were removed, placed in 24-well plates, 50-100. Mu.L of 0.1mg/ml PLO solution was added to the slides, placed at 37 ℃,5% CO 2 An incubator for overnight incubation;
(5) on the 6 th day of differentiation, the PLO is aspirated off, washed 3 times with sterile purified water, followed by adding 50-100. Mu.L of Lamin solution to the slide glass and placing at 37 ℃ 5% 2 Incubating for more than 1h in an incubator;
(6) (ii) digesting day 6 neurospheres into single or very small neurospheres with Accutase, inoculating onto Laminin coated slides and placing at 37 ℃,5% 2 Culturing in a cell culture box, changing liquid every other day, and dyeing after nerve fibers grow out.
(8)CHAT + Culture and preparation of spinal Motor Neuron (MN)
(1) Preparing a mature culture medium in advance according to the formula of the table 4;
(2) will lay HB9 well + Observing the 24-well plate of the spinal cord motor neuron under a microscope from an incubator, and finding that the nerve axons grow out of cell bodies;
(3) the maintenance patterned medium was aspirated, 500. Mu.L of maturation medium per well was slowly added along the walls, incubated at 37 ℃ in a 5% CO2 incubator;
(4) changing the whole or half of the culture solution every other day, and culturing for 6 days to obtain CHAT + Spinal cord motor neurons, nerve filaments winding the edge of the slide in a circle can be observed under a microscope.
3. Cellular immunofluorescence staining
(1) Before cellular immunofluorescence staining, a confining liquid (100 μ L) was prepared in advance according to the following ratio:
89.8. Mu.l PBS medium;
0.2μl Triton-X;
mu.l donkey serum;
primary antibody diluent (100 mu L) is prepared in advance according to the following proportion:
94.8 μ L PBS medium;
0.2. Mu.L of Triton-X solution;
50 μ L donkey serum;
prepare the secondary antibody diluent (100 μ L) in advance according to the following ratio:
95 μ L PBS medium;
50 μ L donkey serum;
(2) After passage, the cells at each stage are inoculated on a glass slide and cultured for 1 to 3 days;
(3) Absorbing the culture medium, washing with PBS culture medium for 2 times, adding 4% paraformaldehyde, and fixing at room temperature for 30min;
(4) Absorbing paraformaldehyde, washing for 3 times with PBS (phosphate buffer solution) culture medium, adding confining liquid, and incubating at room temperature for 1h;
(5) Sucking off the confining liquid, adding primary antibody solution, and incubating overnight at 4 ℃;
(6) The next day, the primary antibody solution was aspirated and washed 3 times with PBS medium for 10min each time;
(7) Adding a secondary antibody solution, adding Hoechest at the same time, and incubating for 45min at room temperature in a dark place;
(8) Removing the secondary antibody solution by suction, washing for 10min with PBS culture medium for 3 times, and then sealing with a sealing agent;
(9) The images were observed with a normal fluorescence microscope or photographed under a confocal microscope.
As shown in fig. 2, wherein fig. 2-a is an immunofluorescence staining pattern of NEP cell positive marker SOX1 (red), nuclear marker Hochest (blue); FIG. 2-B is an immunofluorescence staining pattern of MNP cell positive marker Olig2 (green), nuclear marker Hochest (blue); FIG. 2-C is an immunofluorescence staining pattern for the spinal cord motor neuron positive marker HB9 (green), the neurofilament heavy chain marker NF200 (red); FIG. 2-D is an immunofluorescence staining pattern for the positive marker CHAT (green) and the nuclear marker (Hochest) of mature motor neurons.
4. Mitochondrial fluorescent dye labeling
Mito-Tracker Green is a Green fluorescent probe that can be used for mitochondrial-specific fluorescent staining of living cells. The method comprises the following specific steps:
(1) The neurospheres were first inoculated into PLO and Laminin coated glass dishes and induced to differentiate further.
(2) The fluorescent dye Mito-Tracker Green was diluted with DMEM/F-12 medium to a final concentration of 300nM.
(3) The cells were washed 2 times with DMEM/F-12 medium, the DMEM/F-12 medium was aspirated,adding the prepared fluorescent dye and at 37 deg.C, 5% 2 Incubate 30min.
(4) The dye was aspirated, washed 2 times with DMEM/F-12 medium, replaced with motor neuron medium, immediately observed under a confocal microscope and photographed. As shown in fig. 3.
5. Measurement of mitochondrial length and distribution index
According to the method, after mitochondrial fluorescent dye is marked and photographed, the length and the number of mitochondria in a neuron axon are measured through the function of a curve ROI of ImageJ; the mitochondria were classified and counted according to length of 2, 4, 6 μm. As shown in fig. 3.
Figure 3 shows the distribution and size of mitochondria on axons for D90D and D90A motor neurons, respectively. FIG. 3-A is mitochondria in neurons labeled by Mito-Tracker Green; FIG. 3-B is a statistical result of the distribution of the density of mitochondria on axons; FIG. 3-C is a statistics of the number of mitochondria on axons; FIG. 3-D is a statistical result of mitochondrial size length; FIGS. 3-E are statistics of the proportion of different length mitochondria. In fig. 3, P < 0.05; * P is less than 0.01; * P < 0.001; * P < 0.0001; NS, no design.
6. Measurement of mitochondrial movement
Confocal microscopy delayed real-time live cell imaging was used to detect axonal transport. According to the method, after mitochondrial fluorescent dye is marked and photographed, the marked motor neurons are placed under a confocal microscope for observation, and a video of mitochondrial movement is photographed for 10min, one per 4 seconds. Mitochondrial motion is analyzed by using a kymograph plug-in Image J, and the motion state and the motion direction of mitochondria are counted.
Mitochondria are dynamically transported in neurons to meet their sufficient energy supply and modification of mitochondria, and thus normal transport of mitochondria is an indicator of normal mitochondrial function. Mitochondria were labeled with the fluorescent dye TMRM, mitochondrial motion was photographed under laser confocal, and mitochondrial motion was analyzed by installing kymograph plug-in Image J software, with the results shown in fig. 4A. As shown in FIG. 4B, the ratio of motile mitochondria to total mitochondria was significantly reduced in D90A motor neurons compared to D90D motor neurons, 0.173 + -0.019 in the D90A group, 0.295 + -0.016 in the D90D group, and P < 0.0001. As shown in fig. 4C, the present application also analyzed the direction of mitochondrial movement, and the results showed that the reverse transport ratio of mitochondria of D90A motor nerve was significantly decreased, 0.074 ± 0.012 in D90A group, 0.160 ± 0.020 in D90D group, p =0.0014 in D90D group; the anterograde transport ratio also decreased, but there was no statistical difference between D90D group 0.135 + -0.016 and D90A group 0.099 + -0.014, with P > 0.05. The above results indicate that mitochondria are essentially in a quiescent state in SOD1D 90A ALS motor neurons and retrograde transport is impaired, with no significant change in anterograde transport, indicating that ALS spinomotor neuron retrograde transport is impaired prior to anterograde transport.
7. Mitochondrial potential detection
Mitochondrial potential detection is carried out by using TMRM fluorescent dye, and the specific method is as follows:
(1) Inoculating the motor neurospheres into a glass dish coated by PLO and Laminin, and inducing differentiation through a neural differentiation culture medium for subsequent dye dyeing for later use;
(2) Diluting TMRM dye to 200nM in DMEM/F-12 medium, washing motor neurons 2 times in DMEM/F-12 medium, adding diluted TMRM dye, and diluting at 37 deg.C with 5% CO 2 Incubating in incubator for 30min;
(3) Washing off the dye, washing with DMEM/F-12 culture medium for 2 times, changing into motor neuron culture medium containing 40nM TMRM dye, and observing and taking pictures under confocal microscope;
mitochondrial membrane potential is the fundamental condition for mitochondria to undergo oxidative phosphorylation and constantly produce ATP to maintain cellular function, and a decrease in mitochondrial membrane potential is considered to be the earliest indicator of the onset of apoptosis. D90D and D90A motor neuron mitochondrial potentials were detected by using TMRM fluorescent probes, and the mean fluorescence intensities were counted.
As shown in FIG. 5-B, the mitochondrial potential of D90A motor neurons was significantly lower than that of D90D motor neurons, 29.74 + -2.176 in the D90A group, 45 + -2.248 in the D90D group, and P < 0.001. This indicates mitochondrial dysfunction in D90A motor neurons. The above results demonstrate that the SOD1D 90A mutation affects the membrane potential of motor neurons.
8. Mitochondrial and intracytoplasmic Ca 2+ Measurement of concentration
Rhod-2-AM is a calcium ion fluorescent probe for measuring mitochondrial Ca2+ concentration, while Fluo-4-AM is a fluorescent probe for detecting cytoplasmic Ca2+ concentration. The specific method comprises the following steps:
(1) Inoculating a motor neurosphere into a glass dish coated by PLO and Laminin, and inducing differentiation by using a motor neuron culture medium;
(2) Washing the motor neurons seeded on the glass plate with DMEM/F-12 medium for 2 times, replacing with serum-free medium, adding Rhod-2-AM and Fluo-4-AM dyes to a final concentration of 1. Mu.M, and then incubating at 37 ℃ for 5% CO 2 Incubating in an incubator for 30min;
(3) The medium was aspirated, washed twice with DMEM/F-12 medium, then replaced with motoneuron medium, observed under a confocal microscope and photographed.
Mitochondrial Ca 2+ The concentration is closely related to the function of ALS motor neurons, and the shape and function of mitochondria are closely related to abnormal calcium ion homeostasis. Mitochondrial calcium overload can even lead to neuronal degeneration, and mitochondrial calcium signaling to cell death depends on increased mitochondrial calcium levels and stimulation of apoptosis.
The test first detects the intracytoplasmic and intracytoplasmic calcium ion concentration of D90D and D90A motor neurons by staining with Rhod-2 and Fluo-4, and as a result, it was found that, as shown in FIG. 6-A, the average intensity of Rhod-2 of D90D neurons should be significantly lower than that of D90A neurons, 12.84 + -0.431 for D90D group, 16.91 + -0.859 for D90A group, and P < 0.0001; however, as shown in FIG. 5-B, the mean fluorescence intensity of Fluo-4 did not change significantly.
9. Real-time fluorescent quantitative Real-time PCR reaction
(1) The reaction system is as follows: the reaction solution was prepared on ice
Reagent | Amount of the use |
SYBR Premix Ex TaqⅡ | 10μl |
PCR Forward Primer | 0.8μl |
PCR Reverse Primer | 0.8μl |
ROX Reference Dye | 0.8μl |
DNA template | 0.8μl |
Sterilized water | 0.8μl |
Total | 0.8μl |
(2) Reaction conditions
Temperature of | Time | Number of cycles | |
95 | 1min | 1 | |
95 | 15s | 40 | |
60℃ | 30s |
The final quantitative PCR result is calculated by using a formula of 2-delta-ct.
Statistical analysis was performed using SPSS 22.0 software, statistical mapping was performed using Graphpad Prism 7.0 software, fluorescence intensity was quantified using Image J software, and each experiment was repeated at least three times. Data are expressed as Mean ± SEM, continuous variable between two groups using student-t test, analysis of two sample rates using chi-square test. All results in this study were defined as statistically different as P < 0.05.
As shown in FIG. 7, since the mitochondrial membrane potential of SOD1D 90A motor neurons is reduced and the membrane potential reduction is an early indicator of mitochondrial apoptosis, the anti-apoptosis genes BCL-2 and BCL-XL and the pro-apoptosis genes BAX and BAK are detected by fluorescence quantitative PCR, and the BCL-XL gene is significantly reduced in D90A motor neurons, while the expression levels of BCL-2, BAX and BAK in D90D and D90A motor neurons are not significantly different statistically.
The practice of the present invention has been described in detail in the foregoing detailed description, however, the present invention is not limited to the specific details in the foregoing embodiment. Within the scope of the claims and the technical idea of the invention, a number of simple modifications and changes can be made to the technical solution of the invention, and these simple modifications are within the scope of protection of the invention.
Claims (10)
1. A method for inducing and obtaining spinal cord motor neurons by using human pluripotent stem cells is characterized by comprising the following steps:
s1, adding human pluripotent stem cells into an induced differentiation culture medium containing a first small molecule composition, and inducing and differentiating to obtain neuroepithelial cells;
the first small molecule composition comprises a GSK3 inhibitor, a TGF-beta/Smad inhibitor and a BMP inhibitor;
s2, adding the neuroepithelial cells obtained in the step S1 into a patterned culture medium containing a second small molecule composition, and inducing and differentiating to obtain spinal cord motor neuron progenitor cells;
the second small molecule composition comprises a GSK3 inhibitor, a TGF-beta/Smad inhibitor, a BMP inhibitor, a RAR nuclear receptor activator, and a SHH agonist;
s3, adding the spinal cord motor neuron progenitor cells obtained in the step S2 into a maintenance patterned culture medium containing a third small molecule composition for suspension culture, and inducing differentiation to obtain HB9 + Spinal motor neurons;
the third small molecule composition comprises a RAR nuclear receptor activator and a SHH agonist;
s4, taking HB9 obtained in the step S3 + Performing adherent culture of spinal motor neurons, performing neurotrophic maturation to obtain CHAT + Spinal motor neurons.
2. The method for obtaining spinal motor neurons by induction using human pluripotent stem cells according to claim 1, wherein in step S1, the differentiation-inducing medium comprises DMEM/F12 and Neurobasal in a volume ratio of 1, and further comprises GlutaMax in a volume fraction of 1%, B27 in a volume fraction of 1%, N-2 in a volume fraction of 0.5%, AA in a volume fraction of 0.1mM, a GSK3 inhibitor in a volume fraction of 3 μ M, a TGF- β/Smad inhibitor in a volume fraction of 2 μ M, and a BMP inhibitor in a volume fraction of 2 μ M.
3. The method for obtaining spinal motor neurons by induction using human pluripotent stem cells according to claim 1, wherein in step S2, the patterned medium comprises DMEM/F12 and Neurobasal in a volume ratio of 1.
4. The method for inducing acquisition of spinal motor neurons using human pluripotent stem cells according to claim 3, wherein in step S2, the second small molecule composition comprises CHIR99021, DMH-1, SB431542, RA and SAG.
5. The method for obtaining spinal motor neurons by induction using human pluripotent stem cells according to claim 1, wherein in step S3, the maintenance patterned medium comprises DMEM/F12 and Neurobasal in a volume ratio of 1, and further comprises GlutaMax in a volume fraction of 1%, B27 in a volume fraction of 1%, N-2 in a volume fraction of 0.5%, AA in a volume fraction of 0.1mM, an RAR nuclear receptor activator in a volume fraction of 0.01 μ M, and an SHH agonist in a volume fraction of 0.1 μ M.
6. The method for inducing and obtaining spinal motor neurons using human pluripotent stem cells according to claim 1, wherein the step S4 comprises: after inducing differentiation for 5 days by the method of step S3, the sterile round slide was placed in a well plate, and PLO solution was dropped on the slide at 37 ℃ and 5% CO 2 Incubating overnight under the environment; absorbing and removing PLO the following day, washing, adding Laminin solution dropwise onto the slide, or using precooled Matrigel alone, and making the content of CO 5% at 37 ℃% 2 Continuously incubating for more than 1h under the environment; finally, the large neurospheres are digested into single spinal cord motor neurons or small neurospheres by using cell digestive juice Accutase(ii) a Inoculating the suspension of spinal motor neurons or small neurospheres on a slide treated by PLO/Lamin or Matrigel for adherent culture for 6-10 days, carrying out neurotrophic maturation to obtain the expression CHAT + Spinal motor neurons.
7. The method for obtaining spinal cord motor neurons using induction of human pluripotent stem cells as claimed in claim 6, wherein in step S4, the composition of the medium for neurotrophic comprises Neurobasal, and further comprises GlutaMax at a volume fraction of 1%, N-2 at a volume fraction of 0.5%, B27 at a volume fraction of 1%, AA at 0.1mM, SAG at 0.1. Mu.M, RA at 0.01. Mu.M, IGF-1 at 10ng/mL, CNTF at 10ng/mL, compound E at 0.1. Mu.M, BDNF at 10ng/mL and GDNF at 10 ng/mL.
8. A spinal cord motor neuron obtained using the method of any one of claims 1-7.
9. A composition or kit for obtaining spinal cord motor neurons by induction of human pluripotent stem cells, comprising the first small molecule composition, the second small molecule composition, and the third small molecule composition according to any one of claims 1-6.
10. The use of spinal cord motor neurons prepared by the method of any one of claims 1 to 6 for studying mitochondrial function changes by dynamically observing the visualized changes of the density, motor state, membrane potential and calcium ion concentration of spinal cord motor neurons mitochondria, thereby evaluating drug effects and screening clinical drugs; or for preparing a medicament for treating spinal motor neuron loss or imbalance and dyskinesia and/or sensory disorders caused by nervous system diseases or injuries; or used for the pathological mechanism research and drug screening of the diseases.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210943465.5A CN115404202A (en) | 2022-08-08 | 2022-08-08 | Method for obtaining spinal cord motor neurons by using human pluripotent stem cell induction and application of method in mitochondria visualization |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210943465.5A CN115404202A (en) | 2022-08-08 | 2022-08-08 | Method for obtaining spinal cord motor neurons by using human pluripotent stem cell induction and application of method in mitochondria visualization |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115404202A true CN115404202A (en) | 2022-11-29 |
Family
ID=84159995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210943465.5A Pending CN115404202A (en) | 2022-08-08 | 2022-08-08 | Method for obtaining spinal cord motor neurons by using human pluripotent stem cell induction and application of method in mitochondria visualization |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115404202A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106701824A (en) * | 2017-01-05 | 2017-05-24 | 福建医科大学附属第医院 | Method for obtaining spinal motoneurons and functional cells thereof based on human iPS (induced pluripotent stem) cells |
-
2022
- 2022-08-08 CN CN202210943465.5A patent/CN115404202A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106701824A (en) * | 2017-01-05 | 2017-05-24 | 福建医科大学附属第医院 | Method for obtaining spinal motoneurons and functional cells thereof based on human iPS (induced pluripotent stem) cells |
Non-Patent Citations (2)
Title |
---|
ZHONG-WEI DU等, GENERATION AND EXPANSION OF HIGHLY-PURE MOTOR NEURON PROGENITORS FROM HUMAN PLURIPOTENT STEM CELLS, vol. 6, pages 1 - 17 * |
毛志娟, 肌萎缩侧索硬化患者特异性IPSC细胞系的建立及线粒体功能的初步研究, pages 49 - 59 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ilieva et al. | Psychiatry in a dish: stem cells and brain organoids modeling autism spectrum disorders | |
ES2910032T3 (en) | In vitro differentiation methods of midbrain dopaminergic neurons (mDA) | |
EP1040185B9 (en) | Neural precursor cells, method for the production and use thereof in neural defect therapy | |
CN109136185B (en) | Preparation method and application of brain-like organ device | |
JP2022090133A (en) | Stem cell-derived schwann cells | |
US9205276B2 (en) | Light as a replacement for mitogenic factors on progenitor cells | |
WO2019019223A1 (en) | Neural cell system following directed induction of hipsc differentiation, induction method and application | |
Zhu et al. | Efficient generation of corticofugal projection neurons from human embryonic stem cells | |
EP2617809A2 (en) | Neural stem cells | |
Kumar et al. | Long-term primary culture of neurons taken from chick embryo brain: A model to study neural cell biology, synaptogenesis and its dynamic properties | |
CN113774023B (en) | Construction of human induced pluripotent stem cell induced differentiation nerve cell evaluation model and application of model in evaluation of drug neurotoxicity | |
CN115404202A (en) | Method for obtaining spinal cord motor neurons by using human pluripotent stem cell induction and application of method in mitochondria visualization | |
Nesan et al. | An Efficient method for generating murine hypothalamic neurospheres for the study of regional neural progenitor biology | |
Zhou et al. | Characterization of mitochondrial transport in neurons | |
EP1572879A2 (en) | Method of producing region-specific neurons from human neuronal stem cells | |
Roybon et al. | Stromal cell-derived inducing activity does not promote dopaminergic differentiation, but enhances differentiation and proliferation of neural stem cell-derived astrocytes | |
Djelloul et al. | Reporting on methods to generate and purify rodent and human oligodendrocytes from different sources | |
Noviantari et al. | The expression of nestin in the induced differentiation into neurons of rat bone marrow mesenchymal stem cells by neurotrophin-3 (NT-3) | |
Whitlon et al. | Purification and transfection of cochlear Schwann cells | |
US20130224782A1 (en) | Neurogenesis screening method and system using adipose tissue derived stem cells | |
Mattei | Modeling Human Neurogenesis in vitro using Pluripotent Stem Cells: the Evolution from 2D to 3D | |
US9428730B2 (en) | Coatings and culture media for promoting neurogenesis in adipose tissue derived stem cells | |
Auletta et al. | Native extracellular matrix promotes human neuromuscular organoid morphogenesis and function | |
Günther | Generation of early human neuroepithelial progenitors from primary cells for biomedical applications | |
Mishra et al. | A Simple and Efficient Method for Concomitant Isolation and Culture of Enriched Astroglial and Microglial Cells from the Rat Spinal Cord |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230809 Address after: Room 01-19, 3rd Floor, Building 17, Huagong Science and Technology Park, No. 33 Tangxun Hubei Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430070 Applicant after: Wuhan Hongchen Innovation Biotechnology Co.,Ltd. Address before: 430000 No. 1095 Jiefang Avenue, Wuhan City, Hubei Province Applicant before: Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology |